Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination of Colorectal Cancer



Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination of Colorectal Cancer


Reese W. Randle

Konstantinos I. Votanopoulos

Edward A. Levine

Perry Shen

John H. Stewart IV





PATIENT SELECTION



  • Patient selection is based predominantly on the extent of disease and the functional reserves of the patient.


  • Preoperative evaluation includes complete history and physical, review of previously obtained pathology, and infused computed tomography (CT) of the chest abdomen and pelvis or dedicated abdominal magnetic resonance imaging (MRI). Preoperative lab work includes blood counts, electrolytes, liver function panel, and carcinoembryonic antigen (CEA) levels.


  • Our selection criteria include the following:



    • The patient is medically fit to undergo CRS/HIPEC without signs of kidney, liver, or bone marrow dysfunction preoperatively.


    • The patient’s Eastern Cooperative Oncology Group (ECOG) functional status is less than or equal to 2.


    • There is no extraabdominal disease or retroperitoneal disease.


    • There is low-volume peritoneal disease (preferably a peritoneal carcinomatosis index less than 14) that is potentially completely resectable.


    • Any parenchymal hepatic metastasis should be limited and should not require anatomic liver resection.


  • Malignant ascites and bowel obstructions are predictors of incomplete resection and worse overall survival.


IMAGING AND OTHER DIAGNOSTIC STUDIES



  • Infused CT of the chest, abdomen, and pelvis is the standard preoperative imaging study and helps to rule out extraabdominal disease, extensive hepatic metastases, and insurmountable small bowel involvement. Sites of impending obstruction may also be identified.


  • Although the sensitivity of CT scan for detecting PSD is low, it is useful in determining overall operability. Solid disease components may be hidden in patients with large volumes of malignant ascites (FIG 1).


  • MRI may detect PSD with up to 100% sensitivity, yet has a significantly high false-positive rate, especially after prior operations. This is because MRI is incapable of recognizing a difference between scar tissue and recurrent PSD.


  • Positron emission tomography (PET) is rarely used given that sensitivity and specificity are prohibitively low, especially in patients with limited disease.


  • Endoscopy can allow clinicians to tattoo second colonic primaries in less than 5% of the patients. Endoscopic ultrasonography is unlikely to change the management of these patients.


  • Diagnostic laparoscopy can assist in determining the extent and stage of PSD prior to CRS/HIPEC.


  • The peritoneal carcinomatosis index (PCI) is the most commonly used staging system for PSD. It provides a way to
    standardize the extent of disease. It has been shown to have prognostic value and certain scores have been used as a cutoff in deciding when CRS/HIPEC is appropriate. Calculating the PCI involves dividing the abdomen into nine regions and the small bowel into four regions. For each region, a score of 0 (no tumor), 1 (tumor up to 0.5 cm), 2 (tumor up to 5 cm), or 3 (tumor >5 cm) is applied to assist in understanding tumor burden. Scores for each of the 12 regions are tabulated to derive the PCI score.






    FIG 1 • Infused CT of a patient with large volume of malignant ascites. The PCI is calculated based on the size of solid disease components but it is not possible to distinguish solid components from ascitic fluid in patients with a large volume of malignant ascites. In these cases, we use the ascites score to evaluate patients for the operation.


  • We calculate ascites score in patients with voluminous ascites (FIG 2) based on preoperative imaging. Patient with colorectal primaries and ascites score greater than 3 (or three out of nine abdominal areas with ascitic fluid while on supine position on the CT table) have minimal chances to achieve a complete CRS. In these patients, we start the operation with diagnostic laparoscopy to establish resectability.


SURGICAL MANAGEMENT


Preoperative Planning



  • Preoperative assessment includes a history and physical, laboratory evaluation consisting of blood counts, comprehensive metabolic panel, CEA, and a blood type with crossmatch of four units of packed red blood cells.


  • Splenectomy vaccines are routinely administered at least 2 weeks prior to the operation when splenectomy is anticipated.


  • At the surgeon’s discretion, ureteral stents may be placed prior to incision. This is generally appropriate for patients with a good possibility of ureteral involvement, prior retroperitoneal surgical exploration, or large volume of disease.


  • A bowel preparation is routine. Patients with a bowel obstruction may benefit from the use of enemas.


  • Prophylactic antibiotics are administered prior to induction of anesthesia.


  • Both mechanical and pharmacologic deep vein thrombosis (DVT) prophylaxis is instituted as appropriate.






FIG 2 • Schematic for calculating the ascites score. One point is assigned for the presence of malignant ascites in each of nine abdominal regions on supine CT. The nine regions correlate with those used to calculate the PCI.


Positioning and Team Setup



  • The majority of patients are placed supine. In cases of rectal cancer, induced PSD at modified lithotomy position is preferred (FIG 3).


  • In the modified lithotomy position, the legs are placed in Allen or Yellofin stirrups. All pressure points are padded to prevent neurovascular injuries and/or calf myonecrosis.


  • The thighs are positioned level with the abdomen, as this allows placement of a self-retaining retractor without creating excessive pressure between the retractor and the patient’s thighs.


  • The perineum is positioned flush with the edge of the operating room table.


  • The arms are placed in a neutral position and supported with suitable armrests.


  • The surgeon starts at the patient’s right side, with the assistant standing to the patient’s left side and with the scrub nurse standing to the surgeon’s right side (FIG 4). If the patient is in a modified lithotomy position, a second assistant would be standing in between the patient’s legs.







FIG 3 • Patient positioning. If a large bowel resection is anticipated, the patient is placed on a modified lithotomy position, with the legs on Yellofin stirrups. The thighs are positioned level with the abdomen, as this allows placement of a self-retaining retractor without creating excessive pressure between the retractor and the patient’s thighs. The arms are tucked. All pressure points are padded to prevent neurovascular injuries and/or calf myonecrosis.






FIG 4 • Team setup. The surgeon starts at the patient’s right side, with the assistant standing to the patient’s left side and with the scrub nurse standing to the surgeon’s right side. A second assistant, if available, stands in between the patient’s legs.

Jul 24, 2016 | Posted by in GENERAL SURGERY | Comments Off on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination of Colorectal Cancer

Full access? Get Clinical Tree

Get Clinical Tree app for offline access